BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog [Reuters]
Iovance Biotherapeutics, Inc. (IOVA)
Last iovance biotherapeutics, inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
iovance.com
Company Research
Source: Reuters
BRIEF-Iovance Biotherapeutics Obtains License To Develop And Commercialize A Novel IL-2 Analog Jan 12 (Reuters) - Iovance Biotherapeutics Inc: * IOVANCE BIOTHERAPEUTICS OBTAINS LICENSE TO DEVELOP AND COMMERCIALIZE A NOVEL IL-2 ANALOG * OBTAINED A LICENSE FROM NOVARTIS TO DEVELOP AND COMMERCIALIZE AN ANTIBODY CYTOKINE ENGRAFTED PROTEIN, REFERRED TO AS IOV-3001 * NOVARTIS IS ALSO ENTITLED TO LOW-TO-MID SINGLE DIGIT ROYALTIES FROM COMMERCIAL SALES OF PRODUCT * UNDER AGREEMENT, CO WILL PAY AN UPFRONT PAYMENT TO NOVARTIS AS WELL AS LOW SINGLE DIGIT MILESTONES Source text for Eikon: Further company coverage:
Show less
Read more
Impact Snapshot
Event Time:
IOVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IOVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IOVA alerts
High impacting Iovance Biotherapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
IOVA
News
- Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024GlobeNewswire
- Iovance Biotherapeutics to Present at Upcoming Conferences [Yahoo! Finance]Yahoo! Finance
- Iovance Biotherapeutics to Present at Upcoming ConferencesGlobeNewswire
- With 63% ownership of the shares, Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is heavily dominated by institutional owners [Yahoo! Finance]Yahoo! Finance
- Where Will Iovance Biotherapeutics Stock Be in 5 Years? [Yahoo! Finance]Yahoo! Finance
IOVA
Earnings
- 2/28/24 - Miss
IOVA
Sec Filings
- 5/1/24 - Form ARS
- 4/29/24 - Form DEFA14A
- 4/29/24 - Form DEF
- IOVA's page on the SEC website